Literature DB >> 6246281

Effect of acyclovir [9-(2-hydroxyethoxymethyl)guanine] on Epstein-Barr virus DNA replication.

B M Colby, J E Shaw, G B Elion, J S Pagano.   

Abstract

The effect of acyclovir [9-(2-hydroxyethoxymethyl)guanine] on Epstein-Barr virus (EBV) DNA replication in the lymphoblastoid cell lines P3HR-1 and Raji is reported. Acyclovir at a concentration of 100 microM completely inhibited EBV DNA synthesis in superinfected Raji cells, but did not inhibit DNA synthesis in mock-infected cells. The number of EBV genome equivalents per cell in the virus-producing cell line P3HR-1 was significantly reduced by acyclovir, whereas the number of latent EBV genomes in Raji cells was not affected by the drug. In situ cytohybridization performed on untreated P3HR-1 cultures revealed the presence of relatively large amounts of EBV DNA in 15 to 20% of the cells. After a 100 microM drug treatment, no P3HR-1 cells contained levels of EBV DNA detectable by in situ cytohybridization. Indirect immunofluorescence studies demonstrated that during treatment with 100 microM acyclovir for 7 days, the percentage of P3HR-1 cells expressing viral capsid antigen was reduced. The EBV DNA remaining in P3HR-1 cells after treatment with 100 microM acyclovir (approximately 14 genomes per cell) had the properties of covalently closed circular DNA with an average molecular weight of 108 X 10(6), as determined by contour length measurements.

Entities:  

Mesh:

Substances:

Year:  1980        PMID: 6246281      PMCID: PMC288736     

Source DB:  PubMed          Journal:  J Virol        ISSN: 0022-538X            Impact factor:   5.103


  32 in total

1.  Partial elimination of latent Epstein-Barr virus genomes from virus-producing cells by cyclohexamide.

Authors:  A Tanaka; M Nonoyama; B Hampar
Journal:  Virology       Date:  1976-03       Impact factor: 3.616

2.  Epstein-Barr virus DNA synthesized in superinfected Raji cells.

Authors:  J E Shaw; T Seebeck; J L Li; J S Pagano
Journal:  Virology       Date:  1977-04       Impact factor: 3.616

Review 3.  Recent progress in Epstein-Barr virus research.

Authors:  M A Epstein; B G Achong
Journal:  Annu Rev Microbiol       Date:  1977       Impact factor: 15.500

4.  The genome of simian virus 40.

Authors:  V B Reddy; B Thimmappaya; R Dhar; K N Subramanian; B S Zain; J Pan; P K Ghosh; M L Celma; S M Weissman
Journal:  Science       Date:  1978-05-05       Impact factor: 47.728

5.  Complete nucleotide sequence of SV40 DNA.

Authors:  W Fiers; R Contreras; G Haegemann; R Rogiers; A Van de Voorde; H Van Heuverswyn; J Van Herreweghe; G Volckaert; M Ysebaert
Journal:  Nature       Date:  1978-05-11       Impact factor: 49.962

6.  Observations on childhood infections with the Epstein-Barr virus.

Authors:  G Henle; W Henle
Journal:  J Infect Dis       Date:  1970-03       Impact factor: 5.226

7.  Immunofluorescence in cells derived from Burkitt's lymphoma.

Authors:  G Henle; W Henle
Journal:  J Bacteriol       Date:  1966-03       Impact factor: 3.490

8.  Morphological and virological investigations on cultured Burkitt tumor lymphoblasts (strain Raji).

Authors:  M A Epstein; B G Achong; Y M Barr; B Zajac; G Henle; W Henle
Journal:  J Natl Cancer Inst       Date:  1966-10       Impact factor: 13.506

9.  Simplified quantitative electron microscopy of biopolymers.

Authors:  D Lang; M Mitani
Journal:  Biopolymers       Date:  1970       Impact factor: 2.505

10.  The activity in vitro against herpes virus of 9-(2-hydroxyethoxymethyl)guanine (acycloguanosine), a new antiviral agent.

Authors:  P Collins; D J Bauer
Journal:  J Antimicrob Chemother       Date:  1979-07       Impact factor: 5.790

View more
  51 in total

1.  A phase 1/2 trial of arginine butyrate and ganciclovir in patients with Epstein-Barr virus-associated lymphoid malignancies.

Authors:  Susan P Perrine; Olivier Hermine; Trudy Small; Felipe Suarez; Richard O'Reilly; Farid Boulad; Joyce Fingeroth; Melissa Askin; Arthur Levy; Steven J Mentzer; Massimo Di Nicola; Alessandro M Gianni; Christoph Klein; Steven Horwitz; Douglas V Faller
Journal:  Blood       Date:  2006-11-21       Impact factor: 22.113

2.  Sinus histiocytosis with massive lymphadenopathy (Rosai-Dorfman disease): response to acyclovir.

Authors:  E M Baildam; C I Ewing; S W D'Souza; R F Stevens
Journal:  J R Soc Med       Date:  1992-03       Impact factor: 5.344

Review 3.  Antiviral therapy: current concepts and practices.

Authors:  B Bean
Journal:  Clin Microbiol Rev       Date:  1992-04       Impact factor: 26.132

4.  Concatameric replication of Epstein-Barr virus: structure of the termini in virus-producer and newly transformed cell lines.

Authors:  H Sato; T Takimoto; S Tanaka; J Tanaka; N Raab-Traub
Journal:  J Virol       Date:  1990-11       Impact factor: 5.103

5.  Interaction of Epstein-Barr virus DNA polymerase and 5'-triphosphates of several antiviral nucleoside analogs.

Authors:  J F Chiou; Y C Cheng
Journal:  Antimicrob Agents Chemother       Date:  1985-03       Impact factor: 5.191

6.  Prolonged inhibitory effect of 9-(1,3-dihydroxy-2-propoxymethyl)guanine against replication of Epstein-Barr virus.

Authors:  J C Lin; M C Smith; J S Pagano
Journal:  J Virol       Date:  1984-04       Impact factor: 5.103

Review 7.  Antiherpes drugs: promises and pitfalls.

Authors:  E de Clercq
Journal:  Eur J Clin Microbiol       Date:  1984-04       Impact factor: 3.267

8.  Simultaneous determination of acyclovir, ganciclovir, and (R)-9-[4-hydroxy-2-(hydroxymethyl)butyl]guanine in human plasma using high-performance liquid chromatography.

Authors:  Dennis R Weller; Henry H Balfour; Heather E Vezina
Journal:  Biomed Chromatogr       Date:  2009-08       Impact factor: 1.902

9.  Acyclovir inhibition of Epstein-Barr virus replication.

Authors:  A K Datta; B M Colby; J E Shaw; J S Pagano
Journal:  Proc Natl Acad Sci U S A       Date:  1980-09       Impact factor: 11.205

10.  Potent inhibition of Epstein-Barr virus by phosphorothioate oligodeoxynucleotides without sequence specification.

Authors:  G Q Yao; S Grill; W Egan; Y C Cheng
Journal:  Antimicrob Agents Chemother       Date:  1993-07       Impact factor: 5.191

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.